Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
ALMSthis companyAlumis Inc.	$6.42	-4.21×	27.54×	345.07×	-33.2×	-85.0%	85.5%	-1776.3%	-1011.7%	-80.8%	-120.2%	-4.5%	0.12×	0.21×	0×	4.34×	0.0%	2	0.06	1	C-
ACRSAclaris Therapeutics, Inc.	$4.18	-5.68×	3.58×	47.18×	-5.45×	-122.2%	73.3%	-975.9%	-829.6%	-63.0%	-57.7%	-12.8%	0.02×	0.28×	0×	5.28×	0.0%	2	-2.65	1	D+
ALDXAldeyra The	$0.65	-9.25×	7.03×	0×	-8.1×	55.2%	0.0%	0.0%	0.0%	-76.5%	-59.0%	-10.7%	0.35×	1.72×	-18.51×	2.58×	0.0%	2	-12.88	2	B-
ANABAnaptysBio, Inc.	$47.50	-70.26×	24.14×	3.83×	9.73×	-639.3%	99.0%	20.4%	-5.6%	-35.6%	14.6%	2.2%	0.38×	-3.24×	0.6×	9.07×	0.0%	5	2.21	3	B
ARTVArtiva Biotherapeutics, Inc.	$4.21	-1.25×	0.95×	0×	-1.1×	-84.3%	0.0%	0.0%	0.0%	-76.3%	-74.9%	-75.7%	0.1×	0.19×	0×	8.61×	0.0%	1	4.66	2	C+
AVTXAvalo Therapeutics, Inc.	$7.02	-3.11×	2.93×	4,125.96×	-2.96×	-86.5%	100.0%	-123601.7%	-132642.4%	-94.2%	-70.2%	-21.1%	0.03×	0.17×	0×	8.14×	0.0%	2	4.43	2	B-
Peer median	—	-5.68×	3.58×	3.83×	-2.96×	-86.5%	73.3%	0.0%	-5.6%	-76.3%	-59.0%	-12.8%	0.1×	0.19×	0×	8.14×	0.0%	2	2.21	2	—